Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Zur Ergebnisliste
Ergebnis 16 von 25
Open Access
    Datensatz exportieren als...
  • BibTeX
Creation of a neovascular age‐related macular degeneration national database using a web‐based platform: Fight Retinal Blindness Spain. Report 1: Visual outcomes
Clinical & experimental ophthalmology, 2022-04, Vol.50 (3), p.312-324
2022
Volltextzugriff (PDF)

Details

Autor(en) / Beteiligte
Titel
Creation of a neovascular age‐related macular degeneration national database using a web‐based platform: Fight Retinal Blindness Spain. Report 1: Visual outcomes
Ist Teil von
  • Clinical & experimental ophthalmology, 2022-04, Vol.50 (3), p.312-324
Ort / Verlag
Melbourne: John Wiley & Sons Australia, Ltd
Erscheinungsjahr
2022
Quelle
Wiley Online Library - AutoHoldings Journals
Beschreibungen/Notizen
  • Background To study the visual outcomes of neovascular AMD (nAMD) treated with anti‐vascular endothelial growth factor (VEGF) drugs at national level. Methods Multicenter national database of nAMD eyes treated with anti‐VEGF intravitreal injections (ranibizumab, aflibercept, bevacizumab) in fixed bimonthly (FB) or treat‐and‐extend (TAE) regimens. Demographics, visual acuity (VA) in logarithm of the minimum angle of resolution (logMAR) ETDRS letters at baseline and subsequent visits, number of injections and visits data were collected using a validated web‐based tool (Fight Retinal Blindness!). Results 1273 eyes (1014 patients) were included, 971 treatment naïve (TN) and 302 previously treated (PT). Baseline VA (mean ± SD) was 57.5 (±19.5) and 62.2 (±17) (p > 0.001), and 24 months final VA was 60.4 (±21.2) and 58.8 (±21.1) (p = 0.326), respectively. Mean VA change at 12/24 months was +4.2/+2.9 letters in TN eyes and +0.1/−3.4 letters in PT eyes (p < 0.001/p < 0.001). The percentage of ≥15 letters gainers/losers at 24 months was 24.8%/14.5% in TN, and 10.3%/15.7% in PT eyes. The median number of injections/visits at 12 months was 7/9 in TN and 6/8 in PT (p = 0.002/p < 0.001) and at 24 months was 11/16 in TN and 11/14 in PT (p = 0.329/p < 0.001). Study drugs included ranibizumab (39.5%), aflibercept (41.2%) and bevacizumab (19.3%). Conclusion Independent, large‐scale national audits are feasible if committed health care professionals are provided with efficient information technology systems to do them. The results described here represent an adequate measurement of the quality of care delivered nationwide and benchmark the clinical management of nAMD at a country level compared to other real‐world international cohorts.
Sprache
Englisch
Identifikatoren
ISSN: 1442-6404
eISSN: 1442-9071
DOI: 10.1111/ceo.14054
Titel-ID: cdi_proquest_miscellaneous_2624947797
Format
–
Schlagworte
Acuity, aflibercept, age‐related macular degeneration, Angiogenesis Inhibitors - therapeutic use, audit, benchmark standard, Bevacizumab, Blindness, Blindness - drug therapy, Demography, Eye, Health care, Humans, Internet, Intravitreal Injections, Macular degeneration, Monoclonal antibodies, national database, national dataset, neovascular AMD, ranibizumab, Ranibizumab - therapeutic use, Receptors, Vascular Endothelial Growth Factor - therapeutic use, Recombinant Fusion Proteins - therapeutic use, Retina, Spain - epidemiology, Treatment Outcome, Vascular endothelial growth factor, Vascular Endothelial Growth Factor A, Visual Acuity, Wet Macular Degeneration - diagnosis, Wet Macular Degeneration - drug therapy

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX